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ABSTRACT
Although asymptomatic carriers of Pneumocystis jirovecii with cystic ﬁbrosis (CF) have been described
previously, the molecular epidemiology of P. jirovecii in CF patients has not yet been clariﬁed. This
study identiﬁed the distribution and dynamic evolution of P. jirovecii genotypes based on the
mitochondrial large-subunit (mt LSU) rRNA gene. The mt LSU rRNA genotypes of P. jirovecii isolates in
33 respiratory samples from CF patients were investigated using nested PCR and direct sequencing.
Three different genotypes were detected: 36.3% genotype 1 (85C ⁄ 248C); 15.1% genotype 2 (85A ⁄ 248C);
42.4% genotype 3 (85T ⁄ 248C); and 6% mixed genotypes. Patients studied during a 1-year follow-up
period showed a continuous colonisation ⁄ clearance cycle involving P. jirovecii and an accumulative
tendency to be colonised with genotype 3.
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INTRODUCTION
Cystic ﬁbrosis (CF) is the most common autoso-
mal recessive disorder in Caucasian populations.
The disease is caused by several mutations in the
CF transmembrane conductance regulator gene
that map on the large arm of chromosome 7
(7q31.2) [1]. This pathology can affect different
organs, including the urogenital and gastrointes-
tinal tracts, but the most serious clinical problem
is the chronic bronchopulmonary manifestation
that causes high morbidity and mortality in these
patients. An important factor that contributes to
the development of pulmonary disease in CF
patients is persistent infection by opportunistic
pathogens, including Pseudomonas aeruginosa,
Staphylococcus aureus and Haemophilus inﬂuenzae
[2].
Pneumocystis jirovecii is an opportunistic fun-
gal pathogen that is associated with severe
pneumonia and pulmonary complications in
immunocompromised individuals, especially in
patients infected with human immunodeﬁciency
virus (HIV). Prophylaxis directed against this
microorganism has decreased the overall inci-
dence of colonisation signiﬁcantly, and signiﬁ-
cant reductions have been observed in the
incidence of pneumocystis pneumonia (PCP)
among HIV-infected patients after starting
highly active anti-retroviral therapy [3]. How-
ever, an increasing number of PCP cases have
been described in HIV-negative immunosup-
pressed patients, e.g., those with haematological
malignancies, transplants or connective tissue
diseases [4,5].
Improved molecular biology techniques, e.g.,
PCR, have allowed the detection of low numbers
of Pneumocystis organisms in samples obtained by
non-invasive methods from colonised subjects.
The use of these more sensitive methods has
demonstrated Pneumocystis colonisation in
10–40% of immunocompetent patients with
different chronic lung diseases [2,6]. More-
over, studies in Spain have revealed the pres-
ence of speciﬁc antibodies to Pneumocystis in
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immunocompetent adults [7], with seroconver-
sion usually occurring during early childhood
[8,9].
Although several studies have used PCR to
detect P. jirovecii in respiratory samples from CF
patients [2,10], the turnover of different geno-
types, based on the mitochondrial large-subunit
(mt LSU) rRNA gene, has not been analysed
previously. The aim of the present study was to
investigate the dynamic colonisation of P. jirovecii
in CF patients from Spain.
PATIENTS AND METHODS
Patients
The study included 33 CF cases (14 males, 19 females; median
age 14.4 years, range 1–35 years) who attended a specialised CF
unit between May 2001 and July 2002. Patients were followed
for a 1-year period and underwent a clinical and biological
examination every 6 months in conjunction with use of a
standardised questionnaire. Sputum specimens were collected
from patients for P. jirovecii screening. Informed consent was
obtained in all cases. The Ethics Committee onClinical Research
of the Virgen del Rocio UniversityHospital approved the study.
Case deﬁnition
A patient colonised with P. jirovecii was deﬁned as an
individual, with no symptoms or thorax radiography signs
of PCP, whose respiratory specimen contained P. jirovecii
DNA detectable by nested PCR in two independent analyses.
Individuals who did not meet these criteria were excluded.
Detection of P. jirovecii
After initial overnight digestion of samples with proteinase
K at 56C, DNA from P. jirovecii was extracted using a
QIAamp DNA mini kit (Qiagen, Hilden, Germany). A two-
step nested PCR protocol was used to amplify the mt LSU
rRNA gene as described previously [11]. In brief, in the
ﬁrst ampliﬁcation round, the external primers pAZ102-E
(5¢-GATGGCTGTTTCCAAGCCCA) and pAZ102-H (5¢-GTG-
TACGTTGCAAAGTACTC) were used to obtain a 346-bp
fragment. The second round of ampliﬁcation used
primers pAZ102-X (5¢-GTGAAATACAAATCGGACTAGG)
and pAZ102-Y (5¢-TCACTTAATATTAATTGGGGAGC) to
yield a 260-bp product. Both PCRs comprised 40 cycles of
ampliﬁcation as described previously [11]. The PCR prod-
ucts were analysed by electrophoresis on agarose 1.5% w ⁄v
gels containing ethidium bromide, and the bands were
visualised by UV light. To prevent false-positive reactions
caused by contamination, pipettes with ﬁlters were used for
all stages of the detection procedure. DNA extraction,
preparation of the reaction mixture, PCR ampliﬁcation and
detection were performed in different laboratory areas. A
positive control was included in each reaction, and all PCRs
included a negative control containing sterile water as
template to detect any possible cross-contamination. All
experiments were repeated at least twice.
Genotype characterisation at the mt LSU rRNA gene of
P. jirovecii
Amplicons from all samples that yielded positive nested PCR
results were sequenced to detect polymorphisms at nucleotide
positions 85 and 248. The PCR products were puriﬁed using
Sephacryl S-400 columns (Amersham Pharmacia Biotech,
Upsala, Sweden) and then re-ampliﬁed using an ABI Prism
dRhodamine Terminator Cycle Sequencing Ready Reaction Kit
(PE Applied Biosystems, Foster City, CA, USA). For each
reaction, 5 lL of PCR product, 4 lL of terminator ready
reaction mix and 3 pmol of primer pAZ102-X were added. The
extension products were puriﬁed by ethanol precipitation to
remove excess dye terminators. Each sample pellet was
resuspended in 12.5 lL of template suppression reagent and
denatured by heating at 95C for 3 min. Sequence analysis was
performed using an ABI Prism 310 Sequencer (PE Applied
Biosystems) according to the manufacturer’s instructions. The
sequences were analysed using the Sequence Navigator v.1.0.1
program (PE Applied Biosystems).
Statistical analysis
The chi-square test with Yates’s correction, or Fisher’s exact
test, was used for assessing differences between proportions,
with p <0.05 considered to be statistically signiﬁcant. Statistical
analyses were performed using SPSS v.13.0 (SPSS Inc.,
Chicago, IL, USA).
RESULTS
Molecular identiﬁcation of P. jirovecii polymor-
phisms in the mt LSU rRNA gene was performed
using DNA isolated from the sputum samples of
33 CF patients. The data allowed the identiﬁcation
of genotypes based on a combination of the six
different polymorphisms described at positions
85 and 248 of the mt LSU rRNA gene. At the time
when P. jirovecii was ﬁrst detected in each CF
patient, genotype 1 (85C ⁄ 248C) was present in
36.3% (12 ⁄ 33) and genotype 2 (85A ⁄ 248C) in
15.1% (5 ⁄ 33) of the patients. However, genotype 3
(85T ⁄ 248C) was the most prevalent, being found
in 42.4% (14 ⁄ 33) of the patients. A mixture of
genotypes was identiﬁed in 6% (2 ⁄ 33) of the
patients (genotypes 2 and 3 in one case; genotypes
1, 2 and 3 in a second case).
The 33 patients were studied for a 1-year
period, with the presence of P. jirovecii being
analysed at baseline, after 6 months and after
12 months. Patients who were positive at some
point during the follow-up period, but who
eventually became negative, were considered to
be clearances. New colonisations were deﬁned as
patients who were negative at baseline and who
became positive at some point during the period
of the study. Table 1 shows that colonisation was
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cleared in 16 cases, although one patient was
recolonised after 12 months. In addition, 18
cases of new colonisation were detected, with
P. jirovecii being identiﬁed after 1 year in 12 cases.
Moreover, four patients maintained a carrier
status throughout the study period.
The distribution of the different P. jirovecii
genotypes during the 1-year study period is
shown in Fig. 1. Genotype 1 was the most
common at baseline, being found in 50% of the
isolates sequenced, while polymorphisms 2 and 3
were each found in 25% of isolates sequenced.
After 6 months, genotypes 1 and 3 were the most
common (46.6% and 40%, respectively), while
genotype 2 was represented by only 6.6% of
isolates, as was a mixture of genotypes 1 and 3.
Finally, after 1 year, the frequencies of genotypes
1 and 2 decreased to 22.2% and 5%, respectively,
while the frequency of isolates with genotype 3
increased to 55.5%, and that of those with mixed
genotypes increased to 16.6%.
P. jirovecii was isolated on at least two occa-
sions from 12 patients. Table 2 summarises the
P. jirovecii genotypes identiﬁed in the sputa of
these 12 colonised CF patients at different times
during the 12-month follow-up period. Before
each patient cleared the microorganism, genotype
3 was found in ﬁve cases, genotype 1 in four
cases, genotype 2 in one case, and mixed geno-
types in two cases (1 and 3). The data conﬁrmed
that P. jirovecii genotypes change frequently with-
in colonised patients.
DISCUSSION
Previous studies have described colonisation ⁄
clearance cycles of Pneumocystis spp. in humans
and non-human primates [12,13]. However, the
present report describes the ﬁrst longitudinal
study in Spanish CF patients in which the turn-
over of P. jirovecii colonisation has been demon-
strated by investigating the distribution of
genotypes, based on polymorphism of the mt
LSU rRNA gene. Overall, the distribution of
genotypes among the CF patients was similar to
that described previously for colonised P. jirovecii
patients from Spain [14]. In the present study,
three different genotypes were identiﬁed among
the CF patients investigated, with genotypes
85C ⁄ 248C and 85T ⁄ 248C accounting for 78.7%
of cases, and genotype 85A ⁄ 248C for 15.1%, with
two cases (6%) involving mixed genotypes. This
distribution is in overall agreement with a previ-
ous study in which genotype 3 accounted for
12.1% of isolates from colonised infants in the
USA [15], similar to the frequency of 12.4%
among isolates from Spanish CF patients. Geno-
type 2 occurred at the lowest frequency, account-
ing for 5% of isolates from the USA and 15.1% of
isolates from Spain. Most differences among the
populations were observed with respect to geno-
type 1 and mixed genotypes, probably because of
the presence of genotype 1 in mixtures of isolates
Table 1. Pneumocystis jirovecii colonisation among cystic
ﬁbrosis patients
No. of cases
(n = 33) 0 months 6 months 12 months
6 + + –
4 + – –
5 – + –
1 + – +
12 – – +
1 – + +
4 + + +
+, positive for P. jirovecii; –, negative for P. jirovecii.
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Fig. 1. Relative frequencies of Pneumocystis jirovecii geno-
types among cystic ﬁbrosis (CF) patients during the study
period.
Table 2. Genotypes of Pneumocystis jirovecii present in cystic ﬁbrosis patients who were colonised on at least two occasions
Patient no. 1 3 5 6 10 11 23 24 27 30 32 33
Genotype at 0 months + G2 G1 + – G1 G3 G1 + G2 G1 G3
Genotype at 6 months G2 + G3 G1 G1 G1 G1 – G3 G1, G3 G3 G3
Genotype at 12 months – G1 G3 – G1 G3 G1, G3 G1 – – – –
+, a positive sample with a low P. jirovecii load for which genotyping could not be performed; –, a sample that was negative for P. jirovecii; G1, 85C ⁄ 248C; G2, 85A ⁄ 248C; G3,
85T ⁄ 248C.
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from US patients. Taken together, both of these
studies, as well as a report of isolates from
patients with chronic pulmonary disease, show
that genotype 3 is found frequently in colonised
patients with a range of pulmonary diseases [14].
Beard et al. [15] have suggested that differences
among genotypes observed in adults with AIDS
and those detected in infants may be caused by an
independent acquisition cycle. The data obtained
in the present study exclude this hypothesis and
show that a different underlying disease may
perhaps determine the presence of a speciﬁc
P. jirovecii mt LSU rRNA genotype.
Recent studies have focused on establishing the
role of different P. jirovecii genotypes in colonised
patients. In this respect, a high frequency of
genotype 3 (85T ⁄ 248C) has now been described in
colonised patients with severe chronic pulmonary
disease [14], in immunocompetent infants from
the USA [12], and in CF patients from Spain [16].
These reports suggest that a different genotype
pattern is found among colonised patients and
immunosuppressed PCP patients. Taken together,
the data suggest that genotype 3 might be the best
adapted to the host setting in immunocompetent
colonised patients.
The most important observation of the current
study is the demonstration of a permanent colo-
nisation ⁄ clearance cycle of P. jirovecii in CF
patients, as has been observed in animal models
[17]. Indeed, as shown in Table 1, patients colon-
ised with Pneumocystis frequently cleared the
microorganism, but some patients who were
negative appeared to become colonised during
the follow-up period. In some cases, patients
maintained a colonisation status throughout the
study period although, as shown in Table 2, there
was a continuous change in mt LSU rRNA
genotypes. The cumulative trend towards geno-
type 3 supports the hypothesis that polymor-
phism 85T ⁄ 248C is the best adapted to patients
with this pathology.
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